Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 11, 2002

View Archived Issues

Vasogen reports preliminary results from pilot study in CLL

Phase II Posurdex trial in persistent macular edema completes enrollment

Patent for p53/taxane combination therapy awarded to Aventis, licensed to Introgen

BioSante licenses triple hormone therapy technology

Liprostin pilot study to begin in January 2003

Hormone replacement therapies and statins in hypercholesterolemic postmenopausal women

AVP-923 for pseudobulbar affect in ALS

Adalimumab safe and effective in rheumatoid arthritis

Renegotiation of licensing agreement for Sarafem

New proapoptotic compounds identified at Cell Pathways

Inhibitors of CDK2, CDK5 and/or GSK-3 covered by Pfizer patent

Dual 5-HT2C/alpha2-adrenoceptor antagonists prepared and tested at Servier

Novel series of alpha4beta1/alpha4beta7 antagonists claimed by Merck

Neurogen synthesizes GLP-1 receptor modulators with utility in diabetes and eating disorders

New proline-based MMP inhibitors in early development at Aventis

MDX-060 has marked antitumor activity in CD30+ lymphoma-bearing mice

Antitumor activity of Geron's telomerase inhibitor reported in presentation at ASH meeting

HDAC inhibitor active against multiple myeloma in vitro and in animal model

Pipecolinate MDR modulators effective in modulating mitoxantrone efflux from AML cells

European approval for Avodart for benign prostatic hyperplasia

Micardis launched in Japan

Superior efficacy and safety demonstrated for GH-9001 versus other anticoagulants in rabbits

GTC begins study of rhATIII in patients with hereditary antithrombin deficiency

Advanced Biotherapy prepares IND for corneal transplant rejection therapy

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
In the clinic for April 21, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Abbott, Agenus, Astrazeneca, Briacell, Clearmind, Greenwich, Intodna,...